FFM
IMVT icon

Fairmount Funds Management’s Immunovant IMVT Stock Holding History

Fairmount Funds Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-750,000
Closed -$28.8M – 18
2023
Q3 		$28.8M Buy
+750,000
New +$17M 3.46% 11

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fairmount Funds Management's IMVT Position: Q4 2023 in Review

Fairmount Funds Management sold out of Immunovant (IMVT) in Q4 2023, closing a stake of 750,000 shares — an estimated $28.8M sold.

Fairmount Funds Management first reported a position in IMVT in Q3 2023 and held it in 1 quarter. The position peaked at $28.8M in Q3 2023. 228 funds tracked by Wall St. Rank hold IMVT as of Q4 2023.

  • Fairmount Funds Management reported no remaining Immunovant position as of Q4 2023 after selling out during the quarter.
  • Fairmount Funds Management sold 750,000 Immunovant shares in Q4 2023, an estimated $28.8M.
  • Fairmount Funds Management first reported a position in Immunovant in Q3 2023 and held it in 1 quarter.
  • Fairmount Funds Management's Immunovant position peaked at $28.8M in Q3 2023.
  • 228 funds tracked by Wall St. Rank held Immunovant as of Q4 2023.

Based on Fairmount Funds Management's 13F filing for Q4 2023, filed 14 Feb 2024.